Merck & Co., Inc. news

   Watch this stock
Showing stories 1 - 10 of about 68   

Articles published

MRK 57.67 +0.07 (0.12%)
price chart
Merck Launches Richard T. Clark Fellowship Program with PSI Partnership
“The Richard T. Clark Fellowship program represents the best of what is possible in private-public partnerships for global health.
Merck & Co and Dashtag plans to acquire 21% stake in Fulford (India) through ...
Merck & Co. Inc. and Dashtag, have decided to acquire 21.07 per cent equity stake (8.22 lakh equity shares) of Fulford (India) through voluntary open offer at a price of Rs 830 per share of Rs.10 each aggregating to Rs.68.22 crore.
BlackRock, Merck top-ranked among US corporate boards-study
Icahn's public company at bottom of list, disputes method. * Outside CEOs seen as top picks. By Scott Malone. BOSTON, July 11 (Reuters) - The boards of BlackRock Inc , Merck & Co Inc and Caterpillar Inc topped a ranking of the most capable boards of ...
America's best and worst boards  Financial Post
37 African American Students Awarded Prestigious UNCF/MERCK Science ...
The Merck Company Foundation is a U.S.-based, private charitable foundation. Established in 1957 by Merck, a global healthcare leader, the Foundation is funded entirely by the company and is Merck's chief source of funding support to qualified non ...
Pre-Market Movers (AIG, DryShips, Merck, Complete Genomics, SAP, Deutsche ...
Merck & Co Inc. (MRK) stock advanced 2.18 percent to $42.11 in pre-market trading. The company plans to close an advanced clinical study of its osteoporosis drug after an interim analysis showed that the trial met its primary efficacy goals, and that ...
Merck tests sleeping pill with fewer side effects
The road to a sleeping pill that offers the snooze-inducing benefits of Ambien and Lunesta, while avoiding next-day grogginess and disorientation, has been paved with failure, tripping up GlaxoSmithKline and Takeda Pharmaceutical Co. Now, Merck & Co.
New Sleeping Pill Thwarts Brain's Up-All-Night Neurons  Bloomberg
Merck Profit Tops Estimates as Sales of Diabetes Drugs Grow
July 27 (Bloomberg) -- Merck & Co., facing generic competition in August to its top-selling asthma drug Singulair, reported second-quarter profit that beat analyst estimates on higher sales of the diabetes medicines Januvia and Janumet.
Merck earnings down, but strength surprises The Street  FiercePharma
Merck Could Have a Home Run in Sight
For long-term fans and shareholders of Merck & Co. (NYSE:MRK), the last 10 years haven't been easy ones. Profits have been stagnant, the stock is down for the period and its best selling drug Singulair (for asthma) is going to lose patent protection in ...
Chimerix strikes drug license deal with Merck
Research Triangle Park-based Chimerix Inc. has entered into a license agreement that grants Merck & Co. Inc. exclusive worldwide rights to its new HIV drug.
Merck licenses 2 new compounds against HIV virus  New York Post
Merck Steps Further into HIV Space  Genetic Engineering News
Merck, Whole Foods, Google, Wang Lo Kat: Intellectual Property
July 17 (Bloomberg) -- Merck & Co. ... The European Union's antitrust chief said he'd rather settle an antitrust probe over claims Google Inc. discriminates against rivals than pursue an enforcement action against the world's largest Web-search engine.